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Abstract
Advances in the genetic basis of kidney disease may mean that genetic testing is increasingly
important in reducing disease morbidity and mortality among patients. However, there is little
research examining patient responses to genetic information for Mendelian and common kidney
diseases. Existing research on kidney and other hereditary cancer syndromes can inform three major
issues relevant to the nephrology context: (1) how patients understand their risk of disease following
genetic counseling and testing; (2) their emotional responses to the information; and (3) their uptake
of recommended risk-reducing strategies. Prior research suggests that genetic counseling and testing
may improve patient understanding of genetics, but patients still might not fully understand the
meaning of their results for disease risk. Genetic counseling and testing does not appear to result in
long-term negative emotional effects among patients who carry mutations or those who do not.
Finally, while genetic counseling and testing may improve adherence to recommended screening
strategies, adherence varies substantially across different risk-reduction options. Previous research
also suggests that computer-based interventions might be a useful adjunct to genetic counseling
approaches. Examining whether and how these prior findings relate to the context of hereditary
kidney disease is an important area for future research.
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Introduction
The completion of the human genome project, and associated advances in genetic research,
has allowed the identification of gene mutations that are associated with hundreds of disease
outcomes, making it possible to determine whether unaffected individuals are at increased risk
of disease.1 Currently, over 1500 genetic or inherited diseases have a clinically based molecular
test available.2 Predictive genetic testing can potentially allow for focused prevention and
screening programs, as well as personalized treatment.
Among the human disease genes that have been identified are genes involved in disorders that
disrupt the structure, function, or developmental patterning of the kidney and urogenital tract.
3 Autosomal dominant polycystic kidney disease can result from mutations in the genes
PKD1 and PKD2; 300,000 individuals in the U.S. have or are at risk for developing this
condition.4,5 A number of hereditary kidney cancer syndromes have been identified with
known gene mutations, including von Hippel-Lindau disease, hereditary papillary renal cancer,
Birt-Hogg-Dubé syndrome, and hereditary leiomyomatosis renal cell carcinoma syndrome.6,
7 Patients affected by these syndromes generally have a younger age of presentation and
multifocal and bilateral renal lesions.8 While hereditary cancer syndromes account for less
than 5% of kidney cancers, identification of these patients is critical, as early screening and
surgical treatment may improve disease-related morbidity and mortality.6,9 Screening may
lead to earlier detection of renal tumors at a stage when treatment may be more effective and
a greater number of surgical options can be considered.10,11 However, patients from families
with hereditary kidney cancer syndromes and their physicians often face difficult decisions
regarding cancer control and quality of life.12 Despite this, little research has examined how
patients respond to genetic testing for hereditary kidney cancers or other kidney-related
diseases.
Discussions of how genetic information might be used with patients in nephrology contexts
can be informed by research conducted with patients affected by hereditary cancer syndromes.
This review will focus on patient responses to genetic counseling and testing for hereditary
breast and ovarian cancer (HBOC) and hereditary nonpolyposis colorectal cancer (HNPCC),
also called Lynch syndrome, as the patient outcomes of predictive genetic testing have been
extensively studied for these diseases.13 More specifically, the review will first briefly
summarize the implications of HBOC and HNPCC genetic testing for patient care. Then,
existing research on patients' cognitive (e.g., risk perception, recall), emotional (e.g., distress,
worry, anxiety) and behavioral responses to this genetic information will be discussed. The
review will then present evidence concerning how the educational content and delivery of
genetic information to patients affect these outcomes. The increasing importance of
considering how patients' health literacy, or their health-related skills and knowledge, might
affect their responses to genetic information will also be addressed, as over one-third of U.S.
adults have limited health literacy.14 The implications of existing research findings for the
context of hereditary kidney diseases will be discussed.
Implications of HBOC and HNPCC genetic information for patient care
The hereditary cancer syndromes HBOC and HNPCC have been extensively described
elsewhere.15 Briefly, for HBOC, mutations in the genes BRCA1 and BRCA2 can lead to greatly
increased risk for both breast and ovarian cancer.15 BRCA genetic testing is currently
recommended for those individuals with a family history suggestive of the presence of a gene
mutation.16 Following genetic testing, patients carrying a mutation and their physicians must
make decisions regarding various risk-reduction options, including prophylactic surgery,
which can greatly decrease cancer risk,15,17 screening (e.g., mammography, ovarian cancer
screening), and chemoprevention (e.g., tamoxifen use). Similarly, HNPCC, which results from
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a germline mutation in one of the identified DNA mismatch repair genes, substantially
increases cancer risk, most notably for colorectal, endometrial, gastric, and ovarian cancers.
15 Mutation carriers are advised to screen more frequently, while, for both HBOC and HNPCC,
individuals found not to carry a familial mutation are advised to follow general population
screening recommendations.18
Currently, genetic testing for hereditary cancer syndromes is generally in conjunction with
comprehensive pre- and post-test genetic counseling by a trained genetic counselor.19 Briefly,
pre-test genetic counseling is a process of informed consent that includes discussion of possible
outcomes of testing, as well as benefits, risks and limitations of testing. In post-test counseling,
the results and their significance are discussed, and medical management is reviewed, including
screening and treatment options.20 The aims of genetic counseling for conditions such as
cancers include: educating patients about the genetic condition, improving the accuracy of their
risk perceptions, and encouraging adoption of risk-reducing behaviors.21,22 The process of
genetic counseling and testing therefore raises a number of important issues, which would be
salient as well to the context of hereditary kidney disease: (1) how patients understand their
disease risk following genetic testing; (2) their emotional responses to the genetic information;
and (3) whether they engage in recommended risk-reducing behaviors following testing. In the
next section of the review, each of these issues will be addressed in turn.
Patient responses to genetic information
Understanding of disease risk following genetic counseling and testing
Existing research studies have examined how patients understand their disease risk following
genetic counseling and testing for hereditary cancer syndromes and, to a lesser extent, whether
patients recall genetic information.13 In a meta-analysis, Braithwaite et al. (2004) observed
that, in controlled trials, genetic counseling improved knowledge of cancer genetics but did
not lead to changes in perceived risk of disease.23 A more recent review found that genetic
counseling may lead to more accurate disease risk perceptions among at least some patients,
and that these effects were sustained at one-year follow-up.24 However, a substantial proportion
of patients continued to either overestimate or underestimate their cancer risk even after
counseling. Other studies have found no differences in perceived risk of HBOC or HNPCC
between mutation carriers and non-carriers at 12 months after genetic testing.1
When examining only studies focused on HBOC, reviews have found that genetic counseling
generally increases patients' knowledge of breast cancer genetics,25 and that genetic counseling
and testing for familial breast cancer appears to improve somewhat accuracy of perceived risk
among patients.26 For example, in a study of 450 women seen at a familial breast cancer clinic,
those who overestimated their disease risk before genetic counseling had significantly lower
risk estimates after counseling, but still tended to overestimate their cancer risk; those who
underestimated their risk initially had significantly higher risk estimates after counseling, but
still underestimated their risk.27 These findings suggest that biased processing of genetic
information may be occurring, such that patients might not fully adjust their estimates of their
disease risk to reflect the information that they receive from health care providers.28
Perceived risk may be a critical variable; one study found that patients with accurate risk
perceptions for colorectal cancer were significantly more likely to have undergone appropriate
screening compared to those with inaccurate perceived risk.18 In the context of HNPCC,
research has shown that mutation carriers had a slight increase in perceived risk of colon cancer
following genetic counseling and testing, while non-carriers had a significant reduction in
perceived risk.29 In another study, nearly all patients remembered whether they had inherited
a familial mutation at one-year follow-up, but mutation carriers understood their colorectal
cancer risk significantly less than non-carriers.30
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In summary, research has shown that genetic counseling and testing appears to improve
knowledge of cancer genetics, but patients might not always correctly interpret their test results.
There is evidence that genetic counseling and testing somewhat improves accuracy of
perceived cancer risk.31 However, none of the existing studies have taken into account patients'
health literacy, and particularly their numeracy, or basic quantitative skills, which could
certainly impact adjustment of risk perceptions.28 Existing research findings suggest that
genetic counseling and testing for hereditary kidney diseases might lead to improved
understanding of disease, but that patients might not fully understand the meaning of their
genetic test results for disease risk. These outcomes need to be examined among nephrology
patients with a greater range of numeracy skills and background knowledge regarding genetics
and kidney disease.
Emotional responses to genetic information
Studies of patients' emotional responses to genetic information for hereditary cancer syndromes
have generally looked for possible harmful outcomes (e.g., distress, anxiety, worry). In a 2005
review, Meiser et al. found that unaffected mutation carriers generally had no adverse
psychological effects, while unaffected non-carriers had reductions in negative emotional
outcomes.32 Others have observed no effects of genetic counseling on general anxiety or
cancer-specific worry in controlled trials, although there is some evidence of short-term
reductions in these outcomes in studies with prospective designs.23 Heshka et al. (2008) found
no evidence of long-term effects of genetic testing for carriers or non-carriers on general
distress, cancer-specific distress, anxiety or depression, although some short-term increases
were observed.1
Comprehensive reviews and long-term studies focused on familial breast cancer have
suggested that adverse psychological outcomes of genetic counseling and testing are
uncommon, although a subgroup of individuals may be at increased risk for negative effects.
33 An evidence review found that, overall, more studies showed decreased breast cancer worry
or anxiety after risk assessment and testing.34 Butow et al. (2003) observed differences in the
effects of genetic counseling and testing for familial breast cancer by carrier status; mutation
carriers did not experience significant increases in depression and anxiety, while non-carriers
experienced reductions.26 Unaffected mutation carriers may experience a short-term increase
in distress after learning their test results, with a return to pre-test levels over time, while non-
carriers may have more immediate and sustained psychological benefits.31,35 Some mutation
carriers may feel strong relief after testing,36 although only low levels of benefit finding have
been reported.37 In the context of HNPCC, studies have consistently shown that unaffected
non-carriers experience psychological benefits, with short- and long-term decreases in anxiety
and depression, while no adverse long-term effects have been observed among unaffected
carriers.32 38
Therefore, the existing literature suggests that genetic testing, when conducted in concert with
comprehensive genetic counseling, may lead to reductions in emotions like anxiety, distress
and depression among unaffected non-carriers, with no long-term adverse effects among
unaffected carriers. These findings therefore suggest that long-term negative psychological
outcomes of genetic testing for hereditary kidney diseases are unlikely, although no research
has directly addressed this question to date. Future studies are also needed to examine the
emotional responses of nephrology patients with limited health literacy, whose lower levels of
baseline skills and knowledge might affect both cognitive and emotional responses to the large
amount of information generally given during the genetic counseling and testing process.
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Uptake of screening and surgical options following genetic testing
Much recent research has focused on examining patient decision making for and use of risk-
reduction strategies following genetic counseling and testing for hereditary cancer syndromes.
In their review, Beery et al. (2007) found that genetic testing was associated with increased
adherence to surveillance and screening guidelines in some populations, with greater use of
risk-reducing surgeries among mutation carriers than non-carriers.13 Substantial differences
have been observed across risk-reduction options and disease outcomes, however.
Heshka et al. (2008) observed that mammography rates generally increased in carriers after
disclosure of BRCA1/2 test results compared to rates pre-disclosure, with use of both breast
and ovarian cancer screening generally higher in carriers than non-carriers.1 Carriers' use of
different screening strategies has varied substantially, however, with higher rates of
mammography use than ovarian cancer screening.1 Although U.S. studies published since 2003
indicate a shift toward greater uptake of prophylactic surgery in BRCA1/2 mutation carriers,
the majority of women are still opting for breast cancer surveillance as their primary risk
management strategy.33 Hopwood (2005) observed that, although use of screening seemed to
increase appropriately in mutation carriers, adherence still might not be optimal for carriers or
for non-carriers who are at population risk.31 Observed effects of genetic information regarding
carrier status for BRCA1/2 on screening, chemoprevention, and surgical outcomes are
summarized in Table 1.
Studies examining responses to genetic information for HNPCC have focused on colonoscopy
use. Use of colonoscopy has generally been found to increase in the 12 months following
genetic testing in carriers compared to non-carriers.1 One recent prospective cohort study
observed that carriers increased their use of cancer screening and non-carriers decreased their
use as recommended.29 The few studies investigating gynecological screening in this
population have noted increased adherence after genetic testing.13 Studies examining use of
screening following genetic counseling and testing for HNPCC are summarized in Table 1.
In sum, studies to date have suggested that the majority of both carriers and non-carriers adopt
appropriate screening and preventive behaviors following genetic counseling and testing for
hereditary cancer syndromes.32 However, rates of use vary greatly across different risk-
reduction options, and a notable proportion of mutation carriers are not adherent to
recommendations. Therefore, these findings suggest that genetic testing for hereditary kidney
diseases might somewhat improve adherence to recommended screening such as ocular
evaluation or abdominal imaging. The challenges of hereditary kidney disease, such as younger
age of onset,8 may require additional interventions to achieve recommended use. It is also
important to note that almost all of these studies have included populations of highly educated,
Caucasian women, generally seen in academic specialty centers, and it is unclear to what extent
these results will generalize to broader patient populations. Decision making regarding risk
reduction options may be substantially different in populations with limited health literacy,
who have lower levels of background knowledge, of oral literacy skills required to interact
effectively with physicians, and of numeracy skills required to interpret risk information.
Effects of educational strategies on patient responses to genetic information
The final section of this review will address how the educational content and delivery of genetic
information may play a critical role in patients' understanding of, and subsequent responses to,
their test results.18 Research examining the content of traditional genetic counseling sessions
is limited, but considerable variation has been observed across sessions.39 Edwards et al. (2008)
found that adding content related to genetic risk was effective in improving knowledge and
perceived risk, but that the effects of risk communication interventions on emotional,
behavioral and health outcomes was unclear.40 Audrain et al. (1998) found that patients value
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informational elements in genetic counseling.41 Another study found that discussing
prophylactic surgery during genetic counseling sessions resulted in women from high-risk
breast cancer families having significantly more expectations met.42
Another line of existing research has investigated different delivery approaches for genetic
information, mostly focused on identifying alternatives for educating patients on the basics of
inheritance.22 A recent review of 13 intervention studies, which generally compared
individualized genetic counseling sessions to another type of educational intervention, found
that computer-based and video educational interventions led to the greatest improvement in
genetic knowledge and satisfaction compared to the other approaches, and the computer-based
interventions had better outcomes on psychological measures.43 However, this research base
is limited, as almost all studies have focused on familial breast cancer, and have generally not
examined behavioral outcomes. The main findings of studies comparing educational
approaches for genetic information related to breast and ovarian cancer risk are presented in
Table 2.
In summary, limited research has been conducted to date to examine the effects of educational
content and delivery of genetic information on patient outcomes. Initial research findings that
have potential use in the nephrology context are that computer-based interventions might have
the potential to educate patients about genetics and disease basics. However, as with other
studies in this literature, participants in these studies have generally been highly educated and
Caucasian, and there is no evidence regarding how patients with limited health literacy might
understand and subsequently use presented genetic information. Additional research is needed
on hereditary kidney diseases, as patients might have different reactions to genetic information
related to conditions other than HBOC. Future studies could also examine how interventions
can reach younger patients before the onset of disease.
Conclusions
Despite the increasing importance of advances in the genetic basis of kidney disease, little
research has examined how nephrology patients might respond to such genetic information.
However, existing research on patient responses to information on hereditary breast and
ovarian cancer and hereditary nonpolyposis colorectal cancer can shed light on three major
issues: how patients understand genetic information; their emotional responses to it; and their
uptake of recommended risk-reduction strategies. With regard to the first issue, comprehensive
genetic counseling and testing seems to improve patients' understanding of genetics, but they
still might not fully understand the meaning of genetic test results for their disease risk. Second,
genetic counseling and testing does not appear to result in long-term negative emotional effects
among either mutation carriers or non-carriers. Third, while genetic counseling and testing
may improve adherence to recommended screening, rates of use have varied greatly across
different risk-reduction options. Computer-based interventions might be a useful educational
adjunct for nephrology patients. However, examining whether and how these prior findings
relate to the context of hereditary kidney disease is an important and rich area for future
research.
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Table 1
Effects of genetic information following genetic counseling and testing on use of risk-reducing surgical
procedures, screening and surveillance, and chemoprevention.
Study Sample Follow-up timepoints
after results disclosure
Major results
HBOC
Chen et al.
(2002)44
198 unaffected women
without prior prophylactic or
preventive procedures
After receipt of test
results
BRCA1/2 carriers had significantly higher intentions for
chemoprevention, PM, and PO than non-carriers or those
with unclassified variants (p<.0001)
Graves et al.
(2007)45
435 women affected
with unilateral breast cancer
1, 6 and 12 months Women with uninformative BRCA1/2 test results were less
likely to have received contralateral PM at 12-months than
those with positive test results (OR=0.23; 95% CI:0.08–0.66)
Kinney et al.
(2006)46
40 women from an African
American BRCA1 kindred
12 month No significant increase in mammography screening
observed, regardless of carrier status
Lerman et al.
(2000)47
216 female members of
HBOC families
12 month Carriers had significantly higher rates of mammography
(68%) than non-carriers (44%) (OR= 7.1; 95% CI:1.36–37.1)
Lynch et al.
(2006)36
459 women from HBOC
families
Varying times post
disclosure
53% of carriers and 0% of non-carriers underwent
prophylactic surgeries after disclosure, significantly different
from pre-disclosure (p<.0001)
Rates of TVU significantly increased in carriers (p<.015) and
marginally decreased in non-carriers
Metcalfe et al.
(2005)48
125 unaffected BRCA1/2
carriers
Varying times post
disclosure
12% had used tamoxifen, 10% raloxifene
27% underwent PM, 67% PO
Peshkin et al.
(2002)49
107 unaffected women 12 month No significant difference in use of mammography at 12
months between carriers (59%) and non-carriers (47%)
Phillips et al.
(2006)50
142 unaffected female
BRCA1/2 carriers
3 years Carriers who knew their mutation positive status were
significantly more likely than those who did not know
mutation positive status to undergo all screening practices
except BSE (OR=12.1 for PO; 7.9 for CBE; 7.2 for
mammogram; 30.5 for TVU)
Scheuer et al.
(2002)51
251 unaffected BRCA1/2
carriers
Varying times post
disclosure
Increase in use of mammogram (p=.001), CBE (p=.001),
TVU (p<.001) and CA-125 (p<.001) after disclosure among
those without risk-reducing surgeries
Schwartz et al.
(2003)52
289 high-risk women 1 year Mutation negative individuals (OR=0.03; 95% CI:0.01–0.30)
and BRCA2 carriers (OR=0.23; 95% CI:0.04–1.2)
significantly less likely than BRCA1 carriers to receive bilateral PO
Positive test result also associated with increased use of CA-
125 (p<.001) and TVU (p=.003) ovarian cancer screening
Schwartz et al.
(2004)53
194 newly diagnosed breast
cancer patients at risk for
carrying BRCA1/2 mutation
Surgical decision
after testing
Carriers significantly more likely to choose BLM (48%) than
those with uninformative results (24%) or test decliners (4%)
(p<.001)
Weitzel et al.
(2003)54
37 newly diagnosed breast
cancer patients
Surgical decision
after testing
Carriers significantly more likely to undergo BLM than
unilateral mastectomy (p<.001)
HNPCC
Collins et al.
(2005)55
98 unaffected individuals 12 months Carrier status only significant predictor of colonoscopy at
follow up (OR=20; 95% CI: 5.8–68)
Among women, mutation carriers reported greater use of
TVU (p=.004) and endometrial sampling (p<.001) than non-
carriers
Hadley et al.
(2004)56
56 unaffected individuals
from families with known
HNPCC mutation
6 and 12 months Colonoscopy use significantly higher among carriers than
non-carriers (OR=61.6; 95% CI:5.8–652.6)
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Study Sample Follow-up timepoints
after results disclosure
Major results
Hadley et al.
(2008)29
65 unaffected women in
families with HNPCC
mutation
6 and 12 months Carriers more likely to undergo colonoscopy than non-
carriers at 12 months (p<.0001)
Halbert et al.
(2004)57
98 unaffected adults from
HNPCC families
1, 6 and 12 months Carriers were significantly more likely than test decliners to
have a colonoscopy at 12 months (OR=12.12; 95% CI: 3.42–
42.96); no significant change in colonoscopy use among
non-carriers
Wagner et al.
(2005)58
94 mutation carriers Varying times post
disclosure
Colonoscopy screening increased from 31% to 88% among
carriers (p<.001); gynecological screening increased among
females from 17% to 69% (p<.001)
BLM=bilateral mastectomy
ES=endometrial sampling
PM=prophylactic mastectomy
PO=prophylactic oophorectomy
TVU=transvaginal ultrasound
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Table 2
Effects of different educational approaches for genetic information related to breast and ovarian cancer risk on
cognitive, affective and behavioral intention outcomes.
Study Experimental design Sample Major results
Bowen et al.
(2004)59
Randomized. GC vs.
psychosocial counseling vs.
control group
354 women with breast
cancer family history, not
consistent with BRCA
mutation
Participants in both counseling groups had lower
perceived risk at follow up compared to controls
(p<.01)
Cancer worry decreased in both counseling groups
(p<.05)
Calzone et al.
(2005)60
Randomized. Group vs.
individual pre-test education
session
142 patients at high risk for
carrying BRCA mutation
No significant differences in knowledge or distress
between groups
Green et al.
(2004)61
Randomized. Standard one-
on-one GC vs. computer-
based educational program
and GC
211 women with personal
or family histories of breast
cancer
Mean increase in knowledge significantly higher in
computer group among low-risk women (p=.03) but
not high-risk women
Reduction in perceived risk greatest among low-risk
women in counselor group (p<.001)
Lerman et al.
(1997)62
Randomized. Education vs.
education and non-directive
psychosocial counseling vs.
control
400 women at low to
moderate risk with family
history of breast and/or
ovarian cancer
Significant increases in knowledge in
both intervention groups (p<.001)
Significant increases in perceived limitations and
risks of testing among counseling group (p<.01)
No difference in testing intentions between groups
Lobb et al.
(2002)63
Randomized. Received or
not an audiotape of pre
testing GC session
193 unaffected and
affected women from high
risk breast cancer families
Risk perception less accurate in audiotape
group among unaffected women (p=0.05)
Women in intervention group who listened to the
audiotape had greater reductions in anxiety (p=.02)
and depression (p=.01)
Mancini et al.
(2006)64
Non-randomized. Standard
patient information booklet
vs. no booklet
560 affected women
considering BRCA1/2
testing
Booklet group had greater knowledge (p=.001) and
satisfaction with information provided (p=.001)
Women in booklet group had stronger testing
intentions (p=.009)
Miller et al.
(2005)65
Randomized. Enhanced
counseling vs. general health
information session
following standard GC
77 high-risk women
undergoing BRCA1/2 testing
At 6 months, information seeking about prophylactic
oophorectomy higher in enhanced counseling group
(p=.04)
At 6 months, 28% of those in enhanced counseling
group had undergone prophylactic oophorectomy,
compared to 6% of controls (p=.03)
Skinner et al.
(2002)66
Randomized. Tailored vs.
non-tailored print materials
325 women considering
BRCA1/2 testing with
personal and family
histories of breast and/or
ovarian cancer
Those in tailored materials group had significantly
greater improvement in knowledge (p<.0001) and
less over-estimation of risk of being a mutation
carrier (p<.0001)
No significant differences between groups in anxiety
or expectations about testing
van Roosmalen et
al. (2004)67
Randomized. Received
decision aid or control group
368 affected and
unaffected women being
tested for a BRCA
mutation
Decision aid group more frequently considered
prophylactic surgery at 4 weeks (p=.02)
Decision aid group had more accurate risk
perceptions and felt better informed (p<.01)
No differences between groups for anxiety,
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Study Experimental design Sample Major results
depression, cancer distress
Wakefield et al.
(2008)68
Randomized. Decision aid or
control pamphlet in pre
testing GC session
148 affected and
unaffected women
considering BRCA testing
Decision aid group felt more informed (p=.003) and
had higher knowledge levels (p<.05)
Wang et al.
(2005)69
2×2 factorial design. CD-
ROM program for patients;
feedback checklist for
genetic counselor
197 women attending
BRCA counseling
Patients who viewed CD-ROM significantly less
likely to undergo genetic testing (33% vs. 47%;
OR=0.63; 95% CI: 0.45–0.89)
Feedback group had greater increases in knowledge
(p<.05)
Among those less worried at baseline, the CD-ROM
group had no increase in worry over time, others had
increase in worry (p<.005)
Watson et al.
(1998)70
Randomized. Audiotape vs.
standard consultation
115 women with family
history of breast cancer
Worry decreased in audiotape condition (p=.002)
Audiotape had no effect on recall of genetic risk
estimate
GC=genetic counseling
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